Global Long-acting Melatonin Receptor Agonists Supply, Demand and Key Producers, 2026-2032
The global Long-acting Melatonin Receptor Agonists market size is expected to reach $ 723 million by 2032, rising at a market growth of 6.1% CAGR during the forecast period (2026-2032).
Long-acting melatonin receptor agonists are prescription medicines containing melatonin and formulated with prolonged-release, extended-release, or controlled-release technologies to extend overnight drug release and MT1 and MT2 receptor activity. Commercial products mainly include 2 mg prolonged-release tablets for adults and 1 mg or 5 mg prolonged-release minitablets for pediatric patients. Major indications include primary insomnia and insomnia associated with autism spectrum disorder, Smith-Magenis syndrome, other neurogenetic disorders, and selected pediatric attention-deficit hyperactivity disorder populations. Upstream inputs mainly include pharmaceutical-grade melatonin, modified-release matrix materials, methacrylate copolymers, cellulose derivatives, fillers, coating materials, blister packs, and pharmaceutical bottles. Downstream customers mainly include sleep medicine centers, psychiatric departments, pediatric departments, neurodevelopmental disorder clinics, hospital pharmacies, retail pharmacies, and specialty pharmacies. The market is centered on prescription prolonged-release formulations. Originator pediatric products retain relatively high added value, while adult 2 mg prolonged-release tablets face increasing generic competition, with an overall gross margin generally ranging from approximately 48% to 72%.
From the current market perspective, the long-acting melatonin receptor agonist market consists mainly of adult 2 mg prolonged-release melatonin products and pediatric prolonged-release formulations. The adult segment is concentrated in primary insomnia among older patients and includes both originator and generic products. Pediatric products primarily address insomnia associated with autism spectrum disorder, neurogenetic diseases, and other neurodevelopmental disorders. These populations are smaller but require more specialized diagnosis and treatment, supporting higher unit values for branded pediatric formulations.
Looking ahead, development will increasingly focus on pediatric dosage forms, minitablets, easy-to-swallow formulations, and more consistent overnight release profiles. Manufacturers will optimize release rates, overnight exposure, morning residual effects, and dosing for different age and weight groups. Generic penetration will continue to increase in the adult 2 mg segment, while pediatric products will rely more heavily on proprietary formulations, indication expansion, and specialist promotion.
Key market drivers include population aging, increasing recognition of sleep disorders, improved diagnosis of pediatric neurodevelopmental conditions, and greater physician acceptance of non-GABAergic insomnia treatments. These products are generally not controlled substances and have lower abuse and physical-dependence risks than benzodiazepines and Z-drugs, making them suitable for patients requiring longer treatment or unable to tolerate conventional sedative-hypnotics. Expansion into autism, ADHD, and neurogenetic disorder-related insomnia will create additional prescription demand.
The main constraints include relatively modest clinical efficacy in some patients and variable improvement in sleep onset and maintenance. Low-priced and widely available over-the-counter immediate-release melatonin products create substantial substitution pressure. Regulatory classification of melatonin as a medicine, food, or dietary supplement differs by country, resulting in inconsistent reimbursement, prescribing, and market-access conditions. Generic competition and reimbursement controls will also continue to reduce average selling prices in the adult segment.
This report studies the global Long-acting Melatonin Receptor Agonists demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Long-acting Melatonin Receptor Agonists, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Melatonin Receptor Agonists that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Long-acting Melatonin Receptor Agonists total market, 2021-2032, (USD Million)
Global Long-acting Melatonin Receptor Agonists total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Long-acting Melatonin Receptor Agonists total market, key domestic companies, and share, (USD Million)
Global Long-acting Melatonin Receptor Agonists revenue by player, revenue and market share 2021-2026, (USD Million)
Global Long-acting Melatonin Receptor Agonists total market by Type, CAGR, 2021-2032, (USD Million)
Global Long-acting Melatonin Receptor Agonists total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Long-acting Melatonin Receptor Agonists market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Neurim Pharmaceuticals, Flynn Pharma, Viatris, Teva Pharmaceutical Industries, Aurobindo Pharma, Sandoz, Zentiva, Neuraxpharm, Wockhardt, Medice, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Long-acting Melatonin Receptor Agonists market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Long-acting Melatonin Receptor Agonists Market, By Region:
1. How big is the global Long-acting Melatonin Receptor Agonists market?
2. What is the demand of the global Long-acting Melatonin Receptor Agonists market?
3. What is the year over year growth of the global Long-acting Melatonin Receptor Agonists market?
4. What is the total value of the global Long-acting Melatonin Receptor Agonists market?
5. Who are the Major Players in the global Long-acting Melatonin Receptor Agonists market?
6. What are the growth factors driving the market demand?
Long-acting melatonin receptor agonists are prescription medicines containing melatonin and formulated with prolonged-release, extended-release, or controlled-release technologies to extend overnight drug release and MT1 and MT2 receptor activity. Commercial products mainly include 2 mg prolonged-release tablets for adults and 1 mg or 5 mg prolonged-release minitablets for pediatric patients. Major indications include primary insomnia and insomnia associated with autism spectrum disorder, Smith-Magenis syndrome, other neurogenetic disorders, and selected pediatric attention-deficit hyperactivity disorder populations. Upstream inputs mainly include pharmaceutical-grade melatonin, modified-release matrix materials, methacrylate copolymers, cellulose derivatives, fillers, coating materials, blister packs, and pharmaceutical bottles. Downstream customers mainly include sleep medicine centers, psychiatric departments, pediatric departments, neurodevelopmental disorder clinics, hospital pharmacies, retail pharmacies, and specialty pharmacies. The market is centered on prescription prolonged-release formulations. Originator pediatric products retain relatively high added value, while adult 2 mg prolonged-release tablets face increasing generic competition, with an overall gross margin generally ranging from approximately 48% to 72%.
From the current market perspective, the long-acting melatonin receptor agonist market consists mainly of adult 2 mg prolonged-release melatonin products and pediatric prolonged-release formulations. The adult segment is concentrated in primary insomnia among older patients and includes both originator and generic products. Pediatric products primarily address insomnia associated with autism spectrum disorder, neurogenetic diseases, and other neurodevelopmental disorders. These populations are smaller but require more specialized diagnosis and treatment, supporting higher unit values for branded pediatric formulations.
Looking ahead, development will increasingly focus on pediatric dosage forms, minitablets, easy-to-swallow formulations, and more consistent overnight release profiles. Manufacturers will optimize release rates, overnight exposure, morning residual effects, and dosing for different age and weight groups. Generic penetration will continue to increase in the adult 2 mg segment, while pediatric products will rely more heavily on proprietary formulations, indication expansion, and specialist promotion.
Key market drivers include population aging, increasing recognition of sleep disorders, improved diagnosis of pediatric neurodevelopmental conditions, and greater physician acceptance of non-GABAergic insomnia treatments. These products are generally not controlled substances and have lower abuse and physical-dependence risks than benzodiazepines and Z-drugs, making them suitable for patients requiring longer treatment or unable to tolerate conventional sedative-hypnotics. Expansion into autism, ADHD, and neurogenetic disorder-related insomnia will create additional prescription demand.
The main constraints include relatively modest clinical efficacy in some patients and variable improvement in sleep onset and maintenance. Low-priced and widely available over-the-counter immediate-release melatonin products create substantial substitution pressure. Regulatory classification of melatonin as a medicine, food, or dietary supplement differs by country, resulting in inconsistent reimbursement, prescribing, and market-access conditions. Generic competition and reimbursement controls will also continue to reduce average selling prices in the adult segment.
This report studies the global Long-acting Melatonin Receptor Agonists demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Long-acting Melatonin Receptor Agonists, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Melatonin Receptor Agonists that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Long-acting Melatonin Receptor Agonists total market, 2021-2032, (USD Million)
Global Long-acting Melatonin Receptor Agonists total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Long-acting Melatonin Receptor Agonists total market, key domestic companies, and share, (USD Million)
Global Long-acting Melatonin Receptor Agonists revenue by player, revenue and market share 2021-2026, (USD Million)
Global Long-acting Melatonin Receptor Agonists total market by Type, CAGR, 2021-2032, (USD Million)
Global Long-acting Melatonin Receptor Agonists total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Long-acting Melatonin Receptor Agonists market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Neurim Pharmaceuticals, Flynn Pharma, Viatris, Teva Pharmaceutical Industries, Aurobindo Pharma, Sandoz, Zentiva, Neuraxpharm, Wockhardt, Medice, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Long-acting Melatonin Receptor Agonists market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Long-acting Melatonin Receptor Agonists Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- 1 mg
- 2 mg
- 5 mg
- Other
- Originator Drug
- Generic Drugs
- Prolonged-release
- Extended-release
- Modified-release
- Hospital
- Clinic
- Other
- Neurim Pharmaceuticals
- Flynn Pharma
- Viatris
- Teva Pharmaceutical Industries
- Aurobindo Pharma
- Sandoz
- Zentiva
- Neuraxpharm
- Wockhardt
- Medice
1. How big is the global Long-acting Melatonin Receptor Agonists market?
2. What is the demand of the global Long-acting Melatonin Receptor Agonists market?
3. What is the year over year growth of the global Long-acting Melatonin Receptor Agonists market?
4. What is the total value of the global Long-acting Melatonin Receptor Agonists market?
5. Who are the Major Players in the global Long-acting Melatonin Receptor Agonists market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Long-acting Melatonin Receptor Agonists Introduction
1.2 World Long-acting Melatonin Receptor Agonists Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Long-acting Melatonin Receptor Agonists Total Market by Region (by Headquarter Location)
1.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.3 China Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.4 Europe Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.5 Japan Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.6 South Korea Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.7 ASEAN Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.8 India Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Long-acting Melatonin Receptor Agonists Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.2 World Long-acting Melatonin Receptor Agonists Consumption Value by Region
2.2.1 World Long-acting Melatonin Receptor Agonists Consumption Value by Region (2021-2026)
2.2.2 World Long-acting Melatonin Receptor Agonists Consumption Value Forecast by Region (2027-2032)
2.3 United States Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.4 China Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.5 Europe Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.6 Japan Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.7 South Korea Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.8 ASEAN Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.9 India Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
3 WORLD LONG-ACTING MELATONIN RECEPTOR AGONISTS COMPANIES COMPETITIVE ANALYSIS
3.1 World Long-acting Melatonin Receptor Agonists Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Long-acting Melatonin Receptor Agonists Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Long-acting Melatonin Receptor Agonists in 2025
3.2.3 Global Concentration Ratios (CR8) for Long-acting Melatonin Receptor Agonists in 2025
3.3 Long-acting Melatonin Receptor Agonists Company Evaluation Quadrant
3.4 Long-acting Melatonin Receptor Agonists Market: Overall Company Footprint Analysis
3.4.1 Long-acting Melatonin Receptor Agonists Market: Region Footprint
3.4.2 Long-acting Melatonin Receptor Agonists Market: Company Product Type Footprint
3.4.3 Long-acting Melatonin Receptor Agonists Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Long-acting Melatonin Receptor Agonists Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Long-acting Melatonin Receptor Agonists Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Long-acting Melatonin Receptor Agonists Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Long-acting Melatonin Receptor Agonists Consumption Value Comparison
4.2.1 United States VS China: Long-acting Melatonin Receptor Agonists Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Long-acting Melatonin Receptor Agonists Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Long-acting Melatonin Receptor Agonists Companies and Market Share, 2021-2026
4.3.1 United States Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026)
4.4 China Based Companies Long-acting Melatonin Receptor Agonists Revenue and Market Share, 2021-2026
4.4.1 China Based Long-acting Melatonin Receptor Agonists Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026)
4.5 Rest of World Based Long-acting Melatonin Receptor Agonists Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Long-acting Melatonin Receptor Agonists Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 1 mg
5.2.2 2 mg
5.2.3 5 mg
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Type (2021-2026)
5.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Type (2027-2032)
5.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY PRODUCT STATUS
6.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Product Status: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Product Status
6.2.1 Originator Drug
6.2.2 Generic Drugs
6.3 Market Segment by Product Status
6.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Product Status (2021-2026)
6.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Product Status (2027-2032)
6.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Product Status (2027-2032)
7 MARKET ANALYSIS BY RELEASE PROFILE
7.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Release Profile: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Release Profile
7.2.1 Prolonged-release
7.2.2 Extended-release
7.2.3 Modified-release
7.3 Market Segment by Release Profile
7.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Release Profile (2021-2026)
7.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Release Profile (2027-2032)
7.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Release Profile (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Application (2021-2026)
8.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Application (2027-2032)
8.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Neurim Pharmaceuticals
9.1.1 Neurim Pharmaceuticals Details
9.1.2 Neurim Pharmaceuticals Major Business
9.1.3 Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Product and Services
9.1.4 Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Neurim Pharmaceuticals Recent Developments/Updates
9.1.6 Neurim Pharmaceuticals Competitive Strengths & Weaknesses
9.2 Flynn Pharma
9.2.1 Flynn Pharma Details
9.2.2 Flynn Pharma Major Business
9.2.3 Flynn Pharma Long-acting Melatonin Receptor Agonists Product and Services
9.2.4 Flynn Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Flynn Pharma Recent Developments/Updates
9.2.6 Flynn Pharma Competitive Strengths & Weaknesses
9.3 Viatris
9.3.1 Viatris Details
9.3.2 Viatris Major Business
9.3.3 Viatris Long-acting Melatonin Receptor Agonists Product and Services
9.3.4 Viatris Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Viatris Recent Developments/Updates
9.3.6 Viatris Competitive Strengths & Weaknesses
9.4 Teva Pharmaceutical Industries
9.4.1 Teva Pharmaceutical Industries Details
9.4.2 Teva Pharmaceutical Industries Major Business
9.4.3 Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Product and Services
9.4.4 Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Teva Pharmaceutical Industries Recent Developments/Updates
9.4.6 Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
9.5 Aurobindo Pharma
9.5.1 Aurobindo Pharma Details
9.5.2 Aurobindo Pharma Major Business
9.5.3 Aurobindo Pharma Long-acting Melatonin Receptor Agonists Product and Services
9.5.4 Aurobindo Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Aurobindo Pharma Recent Developments/Updates
9.5.6 Aurobindo Pharma Competitive Strengths & Weaknesses
9.6 Sandoz
9.6.1 Sandoz Details
9.6.2 Sandoz Major Business
9.6.3 Sandoz Long-acting Melatonin Receptor Agonists Product and Services
9.6.4 Sandoz Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Sandoz Recent Developments/Updates
9.6.6 Sandoz Competitive Strengths & Weaknesses
9.7 Zentiva
9.7.1 Zentiva Details
9.7.2 Zentiva Major Business
9.7.3 Zentiva Long-acting Melatonin Receptor Agonists Product and Services
9.7.4 Zentiva Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Zentiva Recent Developments/Updates
9.7.6 Zentiva Competitive Strengths & Weaknesses
9.8 Neuraxpharm
9.8.1 Neuraxpharm Details
9.8.2 Neuraxpharm Major Business
9.8.3 Neuraxpharm Long-acting Melatonin Receptor Agonists Product and Services
9.8.4 Neuraxpharm Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Neuraxpharm Recent Developments/Updates
9.8.6 Neuraxpharm Competitive Strengths & Weaknesses
9.9 Wockhardt
9.9.1 Wockhardt Details
9.9.2 Wockhardt Major Business
9.9.3 Wockhardt Long-acting Melatonin Receptor Agonists Product and Services
9.9.4 Wockhardt Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Wockhardt Recent Developments/Updates
9.9.6 Wockhardt Competitive Strengths & Weaknesses
9.10 Medice
9.10.1 Medice Details
9.10.2 Medice Major Business
9.10.3 Medice Long-acting Melatonin Receptor Agonists Product and Services
9.10.4 Medice Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Medice Recent Developments/Updates
9.10.6 Medice Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Long-acting Melatonin Receptor Agonists Industry Chain
10.2 Long-acting Melatonin Receptor Agonists Upstream Analysis
10.3 Long-acting Melatonin Receptor Agonists Midstream Analysis
10.4 Long-acting Melatonin Receptor Agonists Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Long-acting Melatonin Receptor Agonists Introduction
1.2 World Long-acting Melatonin Receptor Agonists Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Long-acting Melatonin Receptor Agonists Total Market by Region (by Headquarter Location)
1.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.3 China Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.4 Europe Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.5 Japan Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.6 South Korea Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.7 ASEAN Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.3.8 India Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Long-acting Melatonin Receptor Agonists Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.2 World Long-acting Melatonin Receptor Agonists Consumption Value by Region
2.2.1 World Long-acting Melatonin Receptor Agonists Consumption Value by Region (2021-2026)
2.2.2 World Long-acting Melatonin Receptor Agonists Consumption Value Forecast by Region (2027-2032)
2.3 United States Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.4 China Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.5 Europe Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.6 Japan Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.7 South Korea Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.8 ASEAN Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
2.9 India Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032)
3 WORLD LONG-ACTING MELATONIN RECEPTOR AGONISTS COMPANIES COMPETITIVE ANALYSIS
3.1 World Long-acting Melatonin Receptor Agonists Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Long-acting Melatonin Receptor Agonists Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Long-acting Melatonin Receptor Agonists in 2025
3.2.3 Global Concentration Ratios (CR8) for Long-acting Melatonin Receptor Agonists in 2025
3.3 Long-acting Melatonin Receptor Agonists Company Evaluation Quadrant
3.4 Long-acting Melatonin Receptor Agonists Market: Overall Company Footprint Analysis
3.4.1 Long-acting Melatonin Receptor Agonists Market: Region Footprint
3.4.2 Long-acting Melatonin Receptor Agonists Market: Company Product Type Footprint
3.4.3 Long-acting Melatonin Receptor Agonists Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Long-acting Melatonin Receptor Agonists Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Long-acting Melatonin Receptor Agonists Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Long-acting Melatonin Receptor Agonists Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Long-acting Melatonin Receptor Agonists Consumption Value Comparison
4.2.1 United States VS China: Long-acting Melatonin Receptor Agonists Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Long-acting Melatonin Receptor Agonists Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Long-acting Melatonin Receptor Agonists Companies and Market Share, 2021-2026
4.3.1 United States Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026)
4.4 China Based Companies Long-acting Melatonin Receptor Agonists Revenue and Market Share, 2021-2026
4.4.1 China Based Long-acting Melatonin Receptor Agonists Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026)
4.5 Rest of World Based Long-acting Melatonin Receptor Agonists Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Long-acting Melatonin Receptor Agonists Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 1 mg
5.2.2 2 mg
5.2.3 5 mg
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Type (2021-2026)
5.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Type (2027-2032)
5.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY PRODUCT STATUS
6.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Product Status: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Product Status
6.2.1 Originator Drug
6.2.2 Generic Drugs
6.3 Market Segment by Product Status
6.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Product Status (2021-2026)
6.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Product Status (2027-2032)
6.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Product Status (2027-2032)
7 MARKET ANALYSIS BY RELEASE PROFILE
7.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Release Profile: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Release Profile
7.2.1 Prolonged-release
7.2.2 Extended-release
7.2.3 Modified-release
7.3 Market Segment by Release Profile
7.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Release Profile (2021-2026)
7.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Release Profile (2027-2032)
7.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Release Profile (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Long-acting Melatonin Receptor Agonists Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Long-acting Melatonin Receptor Agonists Market Size by Application (2021-2026)
8.3.2 World Long-acting Melatonin Receptor Agonists Market Size by Application (2027-2032)
8.3.3 World Long-acting Melatonin Receptor Agonists Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Neurim Pharmaceuticals
9.1.1 Neurim Pharmaceuticals Details
9.1.2 Neurim Pharmaceuticals Major Business
9.1.3 Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Product and Services
9.1.4 Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Neurim Pharmaceuticals Recent Developments/Updates
9.1.6 Neurim Pharmaceuticals Competitive Strengths & Weaknesses
9.2 Flynn Pharma
9.2.1 Flynn Pharma Details
9.2.2 Flynn Pharma Major Business
9.2.3 Flynn Pharma Long-acting Melatonin Receptor Agonists Product and Services
9.2.4 Flynn Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Flynn Pharma Recent Developments/Updates
9.2.6 Flynn Pharma Competitive Strengths & Weaknesses
9.3 Viatris
9.3.1 Viatris Details
9.3.2 Viatris Major Business
9.3.3 Viatris Long-acting Melatonin Receptor Agonists Product and Services
9.3.4 Viatris Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Viatris Recent Developments/Updates
9.3.6 Viatris Competitive Strengths & Weaknesses
9.4 Teva Pharmaceutical Industries
9.4.1 Teva Pharmaceutical Industries Details
9.4.2 Teva Pharmaceutical Industries Major Business
9.4.3 Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Product and Services
9.4.4 Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Teva Pharmaceutical Industries Recent Developments/Updates
9.4.6 Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
9.5 Aurobindo Pharma
9.5.1 Aurobindo Pharma Details
9.5.2 Aurobindo Pharma Major Business
9.5.3 Aurobindo Pharma Long-acting Melatonin Receptor Agonists Product and Services
9.5.4 Aurobindo Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Aurobindo Pharma Recent Developments/Updates
9.5.6 Aurobindo Pharma Competitive Strengths & Weaknesses
9.6 Sandoz
9.6.1 Sandoz Details
9.6.2 Sandoz Major Business
9.6.3 Sandoz Long-acting Melatonin Receptor Agonists Product and Services
9.6.4 Sandoz Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Sandoz Recent Developments/Updates
9.6.6 Sandoz Competitive Strengths & Weaknesses
9.7 Zentiva
9.7.1 Zentiva Details
9.7.2 Zentiva Major Business
9.7.3 Zentiva Long-acting Melatonin Receptor Agonists Product and Services
9.7.4 Zentiva Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Zentiva Recent Developments/Updates
9.7.6 Zentiva Competitive Strengths & Weaknesses
9.8 Neuraxpharm
9.8.1 Neuraxpharm Details
9.8.2 Neuraxpharm Major Business
9.8.3 Neuraxpharm Long-acting Melatonin Receptor Agonists Product and Services
9.8.4 Neuraxpharm Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Neuraxpharm Recent Developments/Updates
9.8.6 Neuraxpharm Competitive Strengths & Weaknesses
9.9 Wockhardt
9.9.1 Wockhardt Details
9.9.2 Wockhardt Major Business
9.9.3 Wockhardt Long-acting Melatonin Receptor Agonists Product and Services
9.9.4 Wockhardt Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Wockhardt Recent Developments/Updates
9.9.6 Wockhardt Competitive Strengths & Weaknesses
9.10 Medice
9.10.1 Medice Details
9.10.2 Medice Major Business
9.10.3 Medice Long-acting Melatonin Receptor Agonists Product and Services
9.10.4 Medice Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Medice Recent Developments/Updates
9.10.6 Medice Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Long-acting Melatonin Receptor Agonists Industry Chain
10.2 Long-acting Melatonin Receptor Agonists Upstream Analysis
10.3 Long-acting Melatonin Receptor Agonists Midstream Analysis
10.4 Long-acting Melatonin Receptor Agonists Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Long-acting Melatonin Receptor Agonists Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Long-acting Melatonin Receptor Agonists Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Long-acting Melatonin Receptor Agonists Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Long-acting Melatonin Receptor Agonists Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Long-acting Melatonin Receptor Agonists Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Long-acting Melatonin Receptor Agonists Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Long-acting Melatonin Receptor Agonists Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Long-acting Melatonin Receptor Agonists Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Long-acting Melatonin Receptor Agonists Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Long-acting Melatonin Receptor Agonists Players in 2025
Table 12. World Long-acting Melatonin Receptor Agonists Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Long-acting Melatonin Receptor Agonists Company Evaluation Quadrant
Table 14. Head Office of Key Long-acting Melatonin Receptor Agonists Players
Table 15. Long-acting Melatonin Receptor Agonists Market: Company Product Type Footprint
Table 16. Long-acting Melatonin Receptor Agonists Market: Company Product Application Footprint
Table 17. Long-acting Melatonin Receptor Agonists Mergers & Acquisitions Activity
Table 18. United States VS China Long-acting Melatonin Receptor Agonists Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Long-acting Melatonin Receptor Agonists Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (States, Country)
Table 21. United States Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Long-acting Melatonin Receptor Agonists Revenue Market Share (2021-2026)
Table 23. China Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (Province, Country)
Table 24. China Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Long-acting Melatonin Receptor Agonists Revenue Market Share (2021-2026)
Table 26. Rest of World Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Long-acting Melatonin Receptor Agonists Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Long-acting Melatonin Receptor Agonists Revenue Market Share (2021-2026)
Table 29. World Long-acting Melatonin Receptor Agonists Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Long-acting Melatonin Receptor Agonists Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Long-acting Melatonin Receptor Agonists Market Size by Type (2027-2032) & (USD Million)
Table 32. World Long-acting Melatonin Receptor Agonists Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Table 33. World Long-acting Melatonin Receptor Agonists Market Size Value by Product Status (2021-2026) & (USD Million)
Table 34. World Long-acting Melatonin Receptor Agonists Market Size by Product Status (2027-2032) & (USD Million)
Table 35. World Long-acting Melatonin Receptor Agonists Market Size by Release Profile, (USD Million), 2021 & 2025 & 2032
Table 36. World Long-acting Melatonin Receptor Agonists Market Size Value by Release Profile (2021-2026) & (USD Million)
Table 37. World Long-acting Melatonin Receptor Agonists Market Size by Release Profile (2027-2032) & (USD Million)
Table 38. World Long-acting Melatonin Receptor Agonists Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Long-acting Melatonin Receptor Agonists Market Size by Application (2021-2026) & (USD Million)
Table 40. World Long-acting Melatonin Receptor Agonists Market Size by Application (2027-2032) & (USD Million)
Table 41. Neurim Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 42. Neurim Pharmaceuticals Major Business
Table 43. Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Product and Services
Table 44. Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Neurim Pharmaceuticals Recent Developments/Updates
Table 46. Neurim Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Flynn Pharma Basic Information, Manufacturing Base and Competitors
Table 48. Flynn Pharma Major Business
Table 49. Flynn Pharma Long-acting Melatonin Receptor Agonists Product and Services
Table 50. Flynn Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Flynn Pharma Recent Developments/Updates
Table 52. Flynn Pharma Competitive Strengths & Weaknesses
Table 53. Viatris Basic Information, Manufacturing Base and Competitors
Table 54. Viatris Major Business
Table 55. Viatris Long-acting Melatonin Receptor Agonists Product and Services
Table 56. Viatris Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Viatris Recent Developments/Updates
Table 58. Viatris Competitive Strengths & Weaknesses
Table 59. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 60. Teva Pharmaceutical Industries Major Business
Table 61. Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Product and Services
Table 62. Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Teva Pharmaceutical Industries Recent Developments/Updates
Table 64. Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 65. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 66. Aurobindo Pharma Major Business
Table 67. Aurobindo Pharma Long-acting Melatonin Receptor Agonists Product and Services
Table 68. Aurobindo Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Aurobindo Pharma Recent Developments/Updates
Table 70. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 71. Sandoz Basic Information, Manufacturing Base and Competitors
Table 72. Sandoz Major Business
Table 73. Sandoz Long-acting Melatonin Receptor Agonists Product and Services
Table 74. Sandoz Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Sandoz Recent Developments/Updates
Table 76. Sandoz Competitive Strengths & Weaknesses
Table 77. Zentiva Basic Information, Manufacturing Base and Competitors
Table 78. Zentiva Major Business
Table 79. Zentiva Long-acting Melatonin Receptor Agonists Product and Services
Table 80. Zentiva Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Zentiva Recent Developments/Updates
Table 82. Zentiva Competitive Strengths & Weaknesses
Table 83. Neuraxpharm Basic Information, Manufacturing Base and Competitors
Table 84. Neuraxpharm Major Business
Table 85. Neuraxpharm Long-acting Melatonin Receptor Agonists Product and Services
Table 86. Neuraxpharm Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Neuraxpharm Recent Developments/Updates
Table 88. Neuraxpharm Competitive Strengths & Weaknesses
Table 89. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 90. Wockhardt Major Business
Table 91. Wockhardt Long-acting Melatonin Receptor Agonists Product and Services
Table 92. Wockhardt Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Wockhardt Recent Developments/Updates
Table 94. Wockhardt Competitive Strengths & Weaknesses
Table 95. Medice Basic Information, Manufacturing Base and Competitors
Table 96. Medice Major Business
Table 97. Medice Long-acting Melatonin Receptor Agonists Product and Services
Table 98. Medice Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Medice Recent Developments/Updates
Table 100. Medice Competitive Strengths & Weaknesses
Table 101. Global Key Players of Long-acting Melatonin Receptor Agonists Upstream (Raw Materials)
Table 102. Global Long-acting Melatonin Receptor Agonists Typical Customers
Table 1. World Long-acting Melatonin Receptor Agonists Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Long-acting Melatonin Receptor Agonists Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Long-acting Melatonin Receptor Agonists Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Long-acting Melatonin Receptor Agonists Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Long-acting Melatonin Receptor Agonists Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Long-acting Melatonin Receptor Agonists Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Long-acting Melatonin Receptor Agonists Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Long-acting Melatonin Receptor Agonists Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Long-acting Melatonin Receptor Agonists Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Long-acting Melatonin Receptor Agonists Players in 2025
Table 12. World Long-acting Melatonin Receptor Agonists Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Long-acting Melatonin Receptor Agonists Company Evaluation Quadrant
Table 14. Head Office of Key Long-acting Melatonin Receptor Agonists Players
Table 15. Long-acting Melatonin Receptor Agonists Market: Company Product Type Footprint
Table 16. Long-acting Melatonin Receptor Agonists Market: Company Product Application Footprint
Table 17. Long-acting Melatonin Receptor Agonists Mergers & Acquisitions Activity
Table 18. United States VS China Long-acting Melatonin Receptor Agonists Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Long-acting Melatonin Receptor Agonists Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (States, Country)
Table 21. United States Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Long-acting Melatonin Receptor Agonists Revenue Market Share (2021-2026)
Table 23. China Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (Province, Country)
Table 24. China Based Companies Long-acting Melatonin Receptor Agonists Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Long-acting Melatonin Receptor Agonists Revenue Market Share (2021-2026)
Table 26. Rest of World Based Long-acting Melatonin Receptor Agonists Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Long-acting Melatonin Receptor Agonists Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Long-acting Melatonin Receptor Agonists Revenue Market Share (2021-2026)
Table 29. World Long-acting Melatonin Receptor Agonists Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Long-acting Melatonin Receptor Agonists Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Long-acting Melatonin Receptor Agonists Market Size by Type (2027-2032) & (USD Million)
Table 32. World Long-acting Melatonin Receptor Agonists Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Table 33. World Long-acting Melatonin Receptor Agonists Market Size Value by Product Status (2021-2026) & (USD Million)
Table 34. World Long-acting Melatonin Receptor Agonists Market Size by Product Status (2027-2032) & (USD Million)
Table 35. World Long-acting Melatonin Receptor Agonists Market Size by Release Profile, (USD Million), 2021 & 2025 & 2032
Table 36. World Long-acting Melatonin Receptor Agonists Market Size Value by Release Profile (2021-2026) & (USD Million)
Table 37. World Long-acting Melatonin Receptor Agonists Market Size by Release Profile (2027-2032) & (USD Million)
Table 38. World Long-acting Melatonin Receptor Agonists Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Long-acting Melatonin Receptor Agonists Market Size by Application (2021-2026) & (USD Million)
Table 40. World Long-acting Melatonin Receptor Agonists Market Size by Application (2027-2032) & (USD Million)
Table 41. Neurim Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 42. Neurim Pharmaceuticals Major Business
Table 43. Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Product and Services
Table 44. Neurim Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Neurim Pharmaceuticals Recent Developments/Updates
Table 46. Neurim Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Flynn Pharma Basic Information, Manufacturing Base and Competitors
Table 48. Flynn Pharma Major Business
Table 49. Flynn Pharma Long-acting Melatonin Receptor Agonists Product and Services
Table 50. Flynn Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Flynn Pharma Recent Developments/Updates
Table 52. Flynn Pharma Competitive Strengths & Weaknesses
Table 53. Viatris Basic Information, Manufacturing Base and Competitors
Table 54. Viatris Major Business
Table 55. Viatris Long-acting Melatonin Receptor Agonists Product and Services
Table 56. Viatris Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Viatris Recent Developments/Updates
Table 58. Viatris Competitive Strengths & Weaknesses
Table 59. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 60. Teva Pharmaceutical Industries Major Business
Table 61. Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Product and Services
Table 62. Teva Pharmaceutical Industries Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Teva Pharmaceutical Industries Recent Developments/Updates
Table 64. Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
Table 65. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 66. Aurobindo Pharma Major Business
Table 67. Aurobindo Pharma Long-acting Melatonin Receptor Agonists Product and Services
Table 68. Aurobindo Pharma Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Aurobindo Pharma Recent Developments/Updates
Table 70. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 71. Sandoz Basic Information, Manufacturing Base and Competitors
Table 72. Sandoz Major Business
Table 73. Sandoz Long-acting Melatonin Receptor Agonists Product and Services
Table 74. Sandoz Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Sandoz Recent Developments/Updates
Table 76. Sandoz Competitive Strengths & Weaknesses
Table 77. Zentiva Basic Information, Manufacturing Base and Competitors
Table 78. Zentiva Major Business
Table 79. Zentiva Long-acting Melatonin Receptor Agonists Product and Services
Table 80. Zentiva Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Zentiva Recent Developments/Updates
Table 82. Zentiva Competitive Strengths & Weaknesses
Table 83. Neuraxpharm Basic Information, Manufacturing Base and Competitors
Table 84. Neuraxpharm Major Business
Table 85. Neuraxpharm Long-acting Melatonin Receptor Agonists Product and Services
Table 86. Neuraxpharm Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Neuraxpharm Recent Developments/Updates
Table 88. Neuraxpharm Competitive Strengths & Weaknesses
Table 89. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 90. Wockhardt Major Business
Table 91. Wockhardt Long-acting Melatonin Receptor Agonists Product and Services
Table 92. Wockhardt Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Wockhardt Recent Developments/Updates
Table 94. Wockhardt Competitive Strengths & Weaknesses
Table 95. Medice Basic Information, Manufacturing Base and Competitors
Table 96. Medice Major Business
Table 97. Medice Long-acting Melatonin Receptor Agonists Product and Services
Table 98. Medice Long-acting Melatonin Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Medice Recent Developments/Updates
Table 100. Medice Competitive Strengths & Weaknesses
Table 101. Global Key Players of Long-acting Melatonin Receptor Agonists Upstream (Raw Materials)
Table 102. Global Long-acting Melatonin Receptor Agonists Typical Customers
LIST OF FIGURES
Figure 1. Long-acting Melatonin Receptor Agonists Picture
Figure 2. World Long-acting Melatonin Receptor Agonists Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Long-acting Melatonin Receptor Agonists Total Revenue (2021-2032) & (USD Million)
Figure 4. World Long-acting Melatonin Receptor Agonists Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Long-acting Melatonin Receptor Agonists Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 13. Long-acting Melatonin Receptor Agonists Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 16. World Long-acting Melatonin Receptor Agonists Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 18. China Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 23. India Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Long-acting Melatonin Receptor Agonists by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Long-acting Melatonin Receptor Agonists Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Long-acting Melatonin Receptor Agonists Markets in 2025
Figure 27. United States VS China: Long-acting Melatonin Receptor Agonists Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Long-acting Melatonin Receptor Agonists Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Long-acting Melatonin Receptor Agonists Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Type in 2025
Figure 31. 1 mg
Figure 32. 2 mg
Figure 33. 5 mg
Figure 34. Other
Figure 35. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Type (2021-2032)
Figure 36. World Long-acting Melatonin Receptor Agonists Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Figure 37. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Product Status in 2025
Figure 38. Originator Drug
Figure 39. Generic Drugs
Figure 40. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Product Status (2021-2032)
Figure 41. World Long-acting Melatonin Receptor Agonists Market Size by Release Profile, (USD Million), 2021 & 2025 & 2032
Figure 42. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Release Profile in 2025
Figure 43. Prolonged-release
Figure 44. Extended-release
Figure 45. Modified-release
Figure 46. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Release Profile (2021-2032)
Figure 47. World Long-acting Melatonin Receptor Agonists Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Application in 2025
Figure 49. Hospital
Figure 50. Clinic
Figure 51. Other
Figure 52. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Application (2021-2032)
Figure 53. Long-acting Melatonin Receptor Agonists Industrial Chain
Figure 54. Methodology
Figure 55. Research Process and Data Source
Figure 1. Long-acting Melatonin Receptor Agonists Picture
Figure 2. World Long-acting Melatonin Receptor Agonists Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Long-acting Melatonin Receptor Agonists Total Revenue (2021-2032) & (USD Million)
Figure 4. World Long-acting Melatonin Receptor Agonists Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Long-acting Melatonin Receptor Agonists Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Long-acting Melatonin Receptor Agonists Revenue (2021-2032) & (USD Million)
Figure 13. Long-acting Melatonin Receptor Agonists Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 16. World Long-acting Melatonin Receptor Agonists Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 18. China Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 23. India Long-acting Melatonin Receptor Agonists Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Long-acting Melatonin Receptor Agonists by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Long-acting Melatonin Receptor Agonists Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Long-acting Melatonin Receptor Agonists Markets in 2025
Figure 27. United States VS China: Long-acting Melatonin Receptor Agonists Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Long-acting Melatonin Receptor Agonists Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Long-acting Melatonin Receptor Agonists Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Type in 2025
Figure 31. 1 mg
Figure 32. 2 mg
Figure 33. 5 mg
Figure 34. Other
Figure 35. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Type (2021-2032)
Figure 36. World Long-acting Melatonin Receptor Agonists Market Size by Product Status, (USD Million), 2021 & 2025 & 2032
Figure 37. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Product Status in 2025
Figure 38. Originator Drug
Figure 39. Generic Drugs
Figure 40. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Product Status (2021-2032)
Figure 41. World Long-acting Melatonin Receptor Agonists Market Size by Release Profile, (USD Million), 2021 & 2025 & 2032
Figure 42. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Release Profile in 2025
Figure 43. Prolonged-release
Figure 44. Extended-release
Figure 45. Modified-release
Figure 46. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Release Profile (2021-2032)
Figure 47. World Long-acting Melatonin Receptor Agonists Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Application in 2025
Figure 49. Hospital
Figure 50. Clinic
Figure 51. Other
Figure 52. World Long-acting Melatonin Receptor Agonists Market Size Market Share by Application (2021-2032)
Figure 53. Long-acting Melatonin Receptor Agonists Industrial Chain
Figure 54. Methodology
Figure 55. Research Process and Data Source
